Topical oxatomide: An alternative approach for the treatment of vulvar lichen sclerosus

International Journal of Gynecology and Obstetrics

Volumn 55, Issue 3, 1996, Pages 259-264

  Origoni, M ^a   Ferrari, D ^a   Rossi, M ^a   Gandini, F ^a   Sideri, M ^b   Ferrari, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Lichen sclerosus; Oxatomide; Topical treatment; Vulva; Vulvar dystrophy

Indexed keywords

ANTIHISTAMINIC AGENT; OXATOMIDE; PETROLATUM;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; FEMALE; GEL; HUMAN; HUMAN TISSUE; LICHEN SCLEROSUS ET ATROPHICUS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; SYMPTOM; TOPICAL DRUG ADMINISTRATION; VULVA DISEASE;

EID: 0030475387     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(96)02768-3     Document Type: Article

References (30)

1. [1] Kaufman RH, Gardner HL, Brown D Jr, Beyth J. Vulvar dystrophies: an evaluation. Am J Obstet Gynecol 1974; 120: 363.
2. [2] Hart WR, Norris HJ, Helwig EB. Relation of lichen sclerosus and atrophicus of the vulva to the development of carcinoma. Obstet Gynecol 1975; 45: 369.
3. [3] Friedrich EG. Topical testosterone for benign vulvar dystrophy. Obstet Gynecol 1971; 37: 677.
4. [4] Williams GA, Richardson AC, Hathcock EW. Topical testosterone in dystrophic diseases of the vulva. Am J Obstet Gynecol 1966; 96: 21.
5. [5] Zelle K. Treatment of vulvar dystrophies with topical testosterone propionate. Am J Obstet Gynecol 1971; 109: 570.
6. [6] di Paola GR, Balina LM, Gomez Rueda NM. Tratamiento del liquen escleroso atrofico de la vulva con testosterona topica. Rev Argent Gynecol Obstet 1971; 2: 224.
7. [7] Nauth HF. Local testosterone treatment of lichen sclerosus of the vulva. Geburtshilfe Frauenheilkd 1982; 42: 476.
8. [8] Micheletti L, Barbero M, Cavanna L, Preti M, Ghiringhello B, Borgno G. Medical therapy of vulvar dystrophies. Cervix Ifgt 1987; 5: 53.
9. [9] Dalziel KL, Millard PR, Wojnarowska F. The treatment of vulvar lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991; 124: 461.
10. [10] Carli P, Cattaneo A, Giannotti B. Clobetasol 0.05% cream in the treatment of vulvar lichen sclerosus: effect on the immunohistological profile. Br J Dermatol 1992; 127: 542.
11. [11] Dalziel KL, Wojnarowska F. Long-term control of vulvar lichen sclerosus after treatment with a potent topical steroid cream. J Reprod Med 1993; 38: 25.
12. [12] Bracco GL, Carli P, Sonni L. Clinical and histological effects of topical treatments of vulvar lichen sclerosus. A critical evaluation. J Reprod Med 1993; 38: 37.
13. [13] Sideri M, Origoni M, Spinaci L, Ferrari A. Topical testosterone in the treatment of vulvar lichen sclerosus. Int J Gynecol Obstet 1994; 46: 53.
14. [14] Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS. Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1984; 27: 210.
15. [15] Tasaka R, Akagi M, Mio M, Miyoshi K, Nakaya N. Inhibitory effects of oxatomide on intracellular Ca mobilization, Ca uptake and histamine release, using rat peritoneal mast cells. Int Archs Allergy Appl Immunol 1987; 83: 348.
16. [16] Ohmory K, Ishii H, Kubota T, Shuto K, Nakamizo N. Inhibitory effects of oxatomide on several activities of SRS-A and synthetic leukotrienes in guinea-pigs and rats. Arch Int Pharmacodyn Ther 1985; 275: 139.
17. [17] Emanuel MB, Towse GDW. Oxatomide: a new drug combining anti-allergic and antispasmogenic properties. Part I: Pharmacological studies. Medicamentos Act 1980; 16: 19.
18. [18] Van Reempts J, De Clerck F, Borgers M. Oxatomide protects againts degranulation of rat peritoneal mast cells during in vitro challenge with antigen or compound 48/80. Ultrastructural aspects. Agents Actions 1981; 11: 177.
19. [19] Di Lorenzo G. Dati preliminari sull'inibizione della degranulazione dei basofili di pazienti allergici con Oxatomide. Folia Allerg Immunol Clin 1989; 36: 27.
20. [20] Ciprandi G, Cipro G, Paolieri F, Venuti D, Canonica GW. Oxatomide does not influence immune response: further support for its use in allergic disorders. Int J Immunother 1987; 111: 301.
21. [21] Randazzo S.D. L'oxatomide nel trattamento della dermatite atopica. Derm Clin 1985; 5: 297.
22. [22] Pigatto PD, Nicora M, Altomare GF, Morelli M, Finzi AF. L'oxatomide nel trattamento dell'orticaria cronica: valutazione di tollerabilita ed efficacia. G It Dermatol Vener 1987; 122: 25.
23. [23] Balato N, Ayala F, Nappa P, Lembo G, Nicora M. L'oxatomide nella terapia del l'orticaria. G It Dermatol Vener 1988; 123: 1.
24. [24] Zabel M, Lindscheid KR. Die behandlung der chronisch rezidivierenden urtikaria mit den HI-antigonisten Oxatomid und Terfenadin. Therapiewoche 1984; 30: 4454.
25. [25] Manescalchi F, Grimaldi G, Ciccarelli C, Monzani G, Frizzi V. L'oxatomide nel trattamento del prurito del paziente uremico cronico in trattamento emodilico. Basi Raz Ter 1989; 19: 339.
26. [26] Origoni M, Garsia S, Sideri M, Pifarotti G, Nicora M. Efficacy of topical oxatomide in women with pruritus vulvae. Drugs Exptl Clin Res 1990; XVI: 591.
27. [27] Benvenuti C, Nicora F. Farmacovigilanza sull'oxatomide nel trattamento di vane allergopatie in centri specializzati. Studio poticentrico di confronte tra due schemi posologici su 939 casi. J Am Med Assoc 1988; 5 Suppl: 1.
28. [28] Emanueli A, Sacchetti G. Post-marketing surveillance methodology as applied in a pharmaceutical medical department. Secur Medicam 1982; 2: 265.
29. [29] Mehta CR, Patel NR. Network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Statist Assoc 1983; 78: 427.
30. [30] Kendall M, Stuart A. The advanced theory of statistics. New York: McMillan Publishing, 1979.